Literature DB >> 12676841

Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening.

Joël Coste1, Béatrix Cochand-Priollet, Patricia de Cremoux, Catherine Le Galès, Isabelle Cartier, Vincent Molinié, Sylvain Labbé, Marie-Cécile Vacher-Lavenu, Philippe Vielh.   

Abstract

OBJECTIVES: To compare the sensitivity, specificity, and interobserver reliability of conventional cervical smear tests, monolayer cytology, and human papillomavirus testing for screening for cervical cancer.
DESIGN: Cross sectional study in which the three techniques were performed simultaneously with a reference standard (colposcopy and histology).
SETTING: Public university and private practices in France, with complete independence from the suppliers. PARTICIPANTS: 828 women referred for colposcopy because of previously detected cytological abnormalities and 1757 women attending for routine smears. MAIN OUTCOME MEASURES: Clinical readings and optimised interpretation (two blind readings followed, if necessary, by consensus). Sensitivity, specificity, and weighted kappa computed for various thresholds of abnormalities.
RESULTS: Conventional cervical smear tests were more often satisfactory (91% v 87%) according to the Bethesda system, more reliable (weighted kappa 0.70 v 0.57), and had consistently better sensitivity and specificity than monolayer cytology. These findings applied to clinical readings and optimised interpretations, low and high grade lesions, and populations with low and high incidence of abnormalities. Human papillomavirus testing associated with monolayer cytology, whether systematic or for atypical cells of undetermined significance, performed no better than conventional smear tests.
CONCLUSIONS: Monolayer cytology is less reliable and more likely to give false positive and false negative results than conventional cervical smear tests for screening for cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676841      PMCID: PMC152633          DOI: 10.1136/bmj.326.7392.733

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  22 in total

Review 1.  Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

Authors:  K Nanda; D C McCrory; E R Myers; L A Bastian; V Hasselblad; J D Hickey; D B Matchar
Journal:  Ann Intern Med       Date:  2000-05-16       Impact factor: 25.391

2.  Human papillomavirus testing in women with mild cytologic atypia.

Authors:  C Bergeron; D Jeannel; J Poveda; P Cassonnet; G Orth
Journal:  Obstet Gynecol       Date:  2000-06       Impact factor: 7.661

3.  Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma.

Authors:  M L Hutchinson; D J Zahniser; M E Sherman; R Herrero; M Alfaro; M C Bratti; A Hildesheim; A T Lorincz; M D Greenberg; J Morales; M Schiffman
Journal:  Cancer       Date:  1999-04-25       Impact factor: 6.860

4.  Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears. Including initial biopsy results.

Authors:  J W Bishop; S H Bigner; T J Colgan; M Husain; L P Howell; K M McIntosh; D A Taylor; M H Sadeghi
Journal:  Acta Cytol       Date:  1998 Jan-Feb       Impact factor: 2.319

5.  Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy.

Authors:  A Schneider; H Hoyer; B Lotz; S Leistritza; R Kühne-Heid; I Nindl; B Müller; J Haerting; M Dürst
Journal:  Int J Cancer       Date:  2000-11-20       Impact factor: 7.396

6.  Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology.

Authors:  B Cochand-Priollet; C Le Galès; P de Cremoux; V Molinié; X Sastre-Garau; M C Vacher-Lavenu; P Vielh; J Coste
Journal:  Diagn Cytopathol       Date:  2001-06       Impact factor: 1.582

7.  Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer screening system.

Authors:  D R Bolick; D J Hellman
Journal:  Acta Cytol       Date:  1998 Jan-Feb       Impact factor: 2.319

8.  Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

Authors:  M M Manos; W K Kinney; L B Hurley; M E Sherman; J Shieh-Ngai; R J Kurman; J E Ransley; B J Fetterman; J S Hartinger; K M McIntosh; G F Pawlick; R A Hiatt
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

9.  Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection.

Authors:  B M Ronnett; M M Manos; J E Ransley; B J Fetterman; W K Kinney; L B Hurley; J S Ngai; R J Kurman; M E Sherman
Journal:  Hum Pathol       Date:  1999-07       Impact factor: 3.466

10.  Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer.

Authors:  M Poljak; A Brencic; K Seme; A Vince; I J Marin
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

View more
  31 in total

1.  Cervical cancer screening: paragraph for this week in the BMJ was misleading.

Authors:  Jonathan Weintraub
Journal:  BMJ       Date:  2003-07-19

2.  Cervical cancer screening: liquid based cytology is successful.

Authors:  Michael W Whitley
Journal:  BMJ       Date:  2003-07-19

3.  Cervical cancer screening: liquid based cytology may be preferred option for UK screening programme.

Authors:  Thomas Ind
Journal:  BMJ       Date:  2003-07-19

4.  The advantages of incorporating liquid-based cytology (TACAS™) in mass screening for cervical cancer.

Authors:  Yoshihito Yokoyama; Masayuki Futagami; Jun Watanabe; Atsushi Sakuraba; Kazuma Nagasawa; Hidetoshi Maruyama; Shigemi Sato
Journal:  Hum Cell       Date:  2016-01-06       Impact factor: 4.174

Review 5.  The diagnostic value of serum hybrid capture 2 (CH2) HPV DNA in cervical cancer: a systematic review and meta-analysis.

Authors:  Duo Yin; Yan Jiang; Ning Wang; Ling Ouyang; Yanming Lu; Yao Zhang; Heng Wei; Shulan Zhang
Journal:  Tumour Biol       Date:  2014-06-17

6.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

7.  The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings.

Authors:  Marylou Cárdenas-Turanzas; Graciela M Nogueras-Gonzalez; Michael E Scheurer; Karen Adler-Storthz; J L Benedet; J Robert Beck; Michele Follen; Scott B Cantor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

Review 8.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

9.  Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study.

Authors: 
Journal:  BMJ       Date:  2009-07-28

10.  Model for assessing human papillomavirus vaccination strategies.

Authors:  Elamin H Elbasha; Erik J Dasbach; Ralph P Insinga
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.